生物活性

Natalizumab is a recombinant, humanized monoclonal antibody, binds to α4β1-integrin 

and blocks its interaction with vascular cell adhesion molecule-1 (VCAM-1). Natalizumab

can be used for the treatment of relapsing remitting multiple sclerosis and Crohn's disease.

Natalizumab is also the first targeted therapy which blocks an essential mechanism for

lymphocyte entry to the CNS and thus prevents acute demyelinating relapses.

體外研究
(In Vitro)

Natalizumab, a recombinant, humanized antibody, binds to α4β1-integrin and blocks its

interaction with VCAM-1. As a result, leukocyte migration into brain tissue is inhibited,

reducing inflammation and preventing the formation of lesions. Natalizumab may also

inhibit ongoing central nervous system (CNS) inflammation, mediated by leukocytes

already present in the CNS, by interrupting the interactions between α4-integrin-expressing

leukocytes and extracellular matrix proteins such as fibronectin and osteopontin.

MCE has not independently confirmed the accuracy of these methods.

They are for reference only.

體內研究
(In Vivo)

Natalizumab binds rapidly and with high affinity to α4-integrin. Maximal binding (≥80%

saturation), measured in vitro on isolated lymphocyte membranes, occurred 24 hours

after intravenous (IV) doses of natalizumab 1 mg/kg to 6 mg/kg.

MCE has not independently confirmed the accuracy of these methods.

They are for reference only.

CAS 號

 189261-10-7

中文名稱

那他珠單抗

儲存方式

Please store the product under the recommended conditions in the Certificate of Analysis.